Flavio G. Rocha, MD, Hedinger Professor of Surgical Oncology and Physician-in-Chief of the Knight Cancer Institute at Oregon Health & Science University (OHSU), has been announced as a candidate for the American Society of Clinical Oncology (ASCO) Board of Directors in the Designated Surgical Oncologist category.
The position carries a four-year term and provides an opportunity for surgical oncology specialists to contribute to the Society’s leadership and governance.
With a professional background in surgical oncology, academic medicine, and gastrointestinal cancer research, Dr. Rocha brings experience in institutional leadership, scientific programming, and the development of clinical practice guidance.
His previous involvement in ASCO’s Annual Meeting Scientific Program Committee, GI Cancers Symposium Program Committee, and Gastrointestinal Guideline Advisory Group reflects his contributions to the Society’s scientific and educational activities.
Leading Surgical Oncology at OHSU Knight Cancer Institute
Dr. Rocha currently serves as the Hedinger Professor of Surgical Oncology and Physician-in-Chief of the Knight Cancer Institute at Oregon Health & Science University.
His appointments combine academic surgical oncology with institutional clinical leadership, connecting specialized cancer treatment with the broader responsibilities of a comprehensive cancer institute.
Surgical oncology remains an essential component of multidisciplinary cancer care, particularly in gastrointestinal malignancies, where treatment decisions frequently require coordination between surgeons, medical oncologists, radiation oncologists, radiologists, pathologists, and other specialists.
For patients with gastroesophageal, pancreatic, and hepatobiliary cancers, the role of surgery must often be considered alongside systemic treatment, disease staging, and individual patient characteristics.
These complexities make multidisciplinary collaboration particularly important in the management of gastrointestinal cancers.
Dr. Rocha’s academic and institutional positions place him within this evolving area of oncology practice.
A Role in Shaping ASCO’s Scientific Program
Dr. Rocha has contributed to ASCO through several volunteer appointments, including service as the Gastrointestinal Cancer – Gastroesophageal, Pancreatic, and Hepatobiliary Track Chair on the Annual Meeting Scientific Program Committee.
The ASCO Annual Meeting is among the largest international gatherings dedicated to cancer research and clinical oncology, bringing together professionals from multiple specialties to examine new scientific findings and their implications for patient care.
Within the Scientific Program Committee, disease-specific tracks provide a framework for presenting and discussing research across different areas of oncology.
The gastrointestinal cancer track addresses malignancies that continue to present substantial clinical challenges, including pancreatic, gastric, esophageal, liver, and biliary tract cancers.
As Track Chair, Dr. Rocha participated in the scientific programming process for research focused on gastroesophageal, pancreatic, and hepatobiliary malignancies.
His service reflects involvement in the scientific exchange that connects emerging research with the wider oncology community.
Contributing to the GI Cancers Symposium
Dr. Rocha has also served as a member of the ASCO Gastrointestinal Cancers Symposium Program Committee.
The symposium brings together specialists involved in the prevention, diagnosis, treatment, and research of gastrointestinal malignancies.
Its scientific program covers a broad range of topics, including developments in surgical management, systemic therapies, molecular oncology, clinical trials, and multidisciplinary treatment strategies.
Participation in the Program Committee involves contributing to the organization and scientific direction of a meeting dedicated to advances in gastrointestinal cancer care.
Dr. Rocha’s involvement in both the ASCO Annual Meeting and the GI Cancers Symposium demonstrates his engagement with oncology education and the communication of scientific developments to clinicians and researchers.
From Scientific Evidence to Clinical Guidelines
Another component of Dr. Rocha’s ASCO volunteer service has been his membership in the Gastrointestinal Guideline Advisory Group.
Clinical practice guidelines play an important role in translating research findings into evidence-based recommendations that can support treatment decisions.
In gastrointestinal oncology, where therapeutic approaches may involve surgery, chemotherapy, radiation therapy, targeted treatment, and immunotherapy, clinical recommendations must account for an increasingly complex body of evidence.
The development and maintenance of guidelines require ongoing evaluation of clinical research and consideration of its relevance to patient management.
Through his participation in the Gastrointestinal Guideline Advisory Group, Dr. Rocha has contributed to ASCO’s activities related to clinical guidance in gastrointestinal cancer care.
His involvement connects surgical oncology expertise with the broader process of evaluating evidence for multidisciplinary treatment.
The Surgical Oncology Perspective in ASCO Leadership
The Designated Surgical Oncologist position on the ASCO Board of Directors provides representation for surgical oncology within the Society’s governing body.
As cancer treatment continues to evolve, surgical oncologists contribute not only to operative management but also to multidisciplinary treatment planning, clinical research, and the development of evidence-based care strategies.
This is particularly relevant in gastrointestinal oncology, where advances in neoadjuvant treatment, systemic therapy, and patient selection continue to influence the timing and role of surgery.
Dr. Rocha’s candidacy brings together experience in academic surgical oncology, institutional clinical leadership, scientific programming, and guideline-related activities.
His previous service within ASCO has included participation in committees addressing both the presentation of new research and its application to clinical practice.
A New Chapter in ASCO Leadership
Dr. Rocha’s candidacy for the four-year Board of Directors term represents a potential extension of his involvement in ASCO’s scientific and educational initiatives.
His leadership at OHSU Knight Cancer Institute, combined with his contributions to the Annual Meeting Scientific Program Committee, GI Cancers Symposium Program Committee, and Gastrointestinal Guideline Advisory Group, provides a background spanning several areas of contemporary oncology.
If elected, he would bring the perspective of an academic surgical oncologist with experience in gastrointestinal cancer care and institutional leadership to the ASCO Board of Directors.
The election will determine the next representative for the Designated Surgical Oncologist seat, as ASCO prepares for its upcoming leadership term.
Discover more articles like this on OncoDaily.